References
Nasioudis D, Albright BB, Ko EM, Haggerty AF, Giuntoli RL 2nd, Burger RA, Morgan MA, Latif NA (2020) Advanced stage primary mucinous ovarian carcinoma. Where do we stand? Arch Gynecol Obstet 301(4):1047–1054
Babaier A, Ghatage P (2020) Mucinous cancer of the ovary: overview and current status. Diagnostics (Basel) 10(1):52
Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, De Hingh IH, Van Der Velden J, Arts HJ, Massuger LF et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378:230–240
Mercier F, Bakrin N, Bartlett DL, Goere D, Quenet F, Dumont F, Heyd B, Abboud K, Marolho C, The PSOGI Working Group et al (2018) Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multi-institutional cohort from PSOGI and BIG-RENAPE. Ann Surg Oncol 25:1668–1675
Farrell R (2019) Peritonectomy and hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer: what gynaecological oncologists really think. Aust N Z J Obstet Gynaecol 59(3):457–462
Alyami M, Hübner M, Grass F, Bakrin N, Villeneuve L, Laplace N, Passot G, Glehen O, Kepenekian V (2019) Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 20(7):e368–e377
Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA (2018) A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol 150(1):23–30
Author information
Authors and Affiliations
Contributions
All authors whose names appear on the submission: (1) made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work; (2) drafted the work or revised it critically for important intellectual content; (3) approved the version to be published; and (4) agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Iavazzo, C., Spiliotis, J. Is there a promising role of HIPEC in patients with advanced mucinous ovarian cancer?. Arch Gynecol Obstet 303, 597–598 (2021). https://doi.org/10.1007/s00404-020-05636-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-020-05636-w